Search

Your search keyword '"Margreiter, R."' showing total 1,764 results
Start Over Author "Margreiter, R."
1,764 results on '"Margreiter, R."'

1. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Author

Tieken, I., Haasnoot, G., van Meel, M., Rump, L.C., Rosenkranz, A., Horn, S., Margreiter, R., Schneeberger, S., Oberbauer, R., Pohanka, E., Függer, F., Mühlbacher, F., Berlakovich, G., Meurisse, M., Weekers, L., Ysebaert, D., Wissing, K.M., Mikhalski, D., Mourad, M., van Biesen, W., Kuypers, D., Floege, J., Anthuber, M., Viebahn, R., Schenker, P., Budde, K., Pratschke, J., Zidek, W., Melchior, S., Woitas, R., Strassburg, C.H., Hugo, C., Wirth, M., Schiffer, M., Kribben, A., Pisarski, P., Fichtner-Feigl, S., Haubitz, M., Weimer, R., Weithofer, P., Fornara, P., Fisher, L., Sester, U., Zeier, M., Kliem, V., Klempnauer, l, Grimm, M.O., Kunzendorf, U., Stippel, D., Arns, W., Mönch, C., Nitschke, M., Bartels, M., Krämer, B., Kruger, B., Heemann, U., Werner, J., Hoyer, J., Wolters, H.H., Suwelack, B., Lutz, J., Banas, B., Hakenberg, O., Olbricht, C.J., Kalus, M., Schwenger, V., Nadalin, S., Schröppel, B., Lopau, K., Seelen, M.A.J., Berger, S.P., de Fijter, J.W., van der Linden, S.J., Christiaans, M.H.L., van de Wetering, J., van Zuilen, A.D., Bemelman, F., Nurmohamed, A., Hilbrands, L., de Fijter, Johan, Dreyer, Geertje, Mallat, Marko, Budde, Klemens, Pratschke, Johann, Klempnauer, Jürgen, Zeier, Martin, Arns, Wolfgang, Hugo, Christian, Rump, Lars-Christian, Hauser, Ingeborg, Schenker, Peter, Schiffer, Mario, Grimm, Marc-Oliver, Kliem, Volker, Olbricht, Christoph J., Pisarski, Przemyslaw, Banas, Bernhard, Suwelack, Barbara, Hakenberg, Oliver, Berlakovich, Gabriela, Schneeberger, Stefan, van de Wetering, Jacqueline, Berger, Stefan, Bemelman, Frederike, Kuypers, Dirk, Heidt, Sebastiaan, Rahmel, Axel, Claas, Frans, Peeters, Patrick, Oberbauer, Rainer, Heemann, Uwe, and Krämer, Bernhard K.

Published
2023
Full Text
View/download PDF

5. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Author

de Fijter, Johan, primary, Dreyer, Geertje, additional, Mallat, Marko, additional, Budde, Klemens, additional, Pratschke, Johann, additional, Klempnauer, Jürgen, additional, Zeier, Martin, additional, Arns, Wolfgang, additional, Hugo, Christian, additional, Rump, Lars-Christian, additional, Hauser, Ingeborg, additional, Schenker, Peter, additional, Schiffer, Mario, additional, Grimm, Marc-Oliver, additional, Kliem, Volker, additional, Olbricht, Christoph J., additional, Pisarski, Przemyslaw, additional, Banas, Bernhard, additional, Suwelack, Barbara, additional, Hakenberg, Oliver, additional, Berlakovich, Gabriela, additional, Schneeberger, Stefan, additional, van de Wetering, Jacqueline, additional, Berger, Stefan, additional, Bemelman, Frederike, additional, Kuypers, Dirk, additional, Heidt, Sebastiaan, additional, Rahmel, Axel, additional, Claas, Frans, additional, Peeters, Patrick, additional, Oberbauer, Rainer, additional, Heemann, Uwe, additional, Krämer, Bernhard K., additional, Tieken, I., additional, Haasnoot, G., additional, van Meel, M., additional, Rump, L.C., additional, Rosenkranz, A., additional, Horn, S., additional, Margreiter, R., additional, Schneeberger, S., additional, Oberbauer, R., additional, Pohanka, E., additional, Függer, F., additional, Mühlbacher, F., additional, Berlakovich, G., additional, Meurisse, M., additional, Weekers, L., additional, Ysebaert, D., additional, Wissing, K.M., additional, Mikhalski, D., additional, Mourad, M., additional, van Biesen, W., additional, Kuypers, D., additional, Floege, J., additional, Anthuber, M., additional, Viebahn, R., additional, Schenker, P., additional, Budde, K., additional, Pratschke, J., additional, Zidek, W., additional, Melchior, S., additional, Woitas, R., additional, Strassburg, C.H., additional, Hugo, C., additional, Wirth, M., additional, Schiffer, M., additional, Kribben, A., additional, Pisarski, P., additional, Fichtner-Feigl, S., additional, Haubitz, M., additional, Weimer, R., additional, Weithofer, P., additional, Fornara, P., additional, Fisher, L., additional, Sester, U., additional, Zeier, M., additional, Kliem, V., additional, Klempnauer, l, additional, Grimm, M.O., additional, Kunzendorf, U., additional, Stippel, D., additional, Arns, W., additional, Mönch, C., additional, Nitschke, M., additional, Bartels, M., additional, Krämer, B., additional, Kruger, B., additional, Heemann, U., additional, Werner, J., additional, Hoyer, J., additional, Wolters, H.H., additional, Suwelack, B., additional, Lutz, J., additional, Banas, B., additional, Hakenberg, O., additional, Olbricht, C.J., additional, Kalus, M., additional, Schwenger, V., additional, Nadalin, S., additional, Schröppel, B., additional, Lopau, K., additional, Seelen, M.A.J., additional, Berger, S.P., additional, de Fijter, J.W., additional, van der Linden, S.J., additional, Christiaans, M.H.L., additional, van de Wetering, J., additional, van Zuilen, A.D., additional, Bemelman, F., additional, Nurmohamed, A., additional, and Hilbrands, L., additional

Published
2023
Full Text
View/download PDF

9. Hepatocellular carcinoma progression during bridging before liver transplantation

Author

Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., and Neuhaus P.

Abstract

Background: Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria affecting the chance of long-term success. Here, the relationship between pretransplant bridging therapy and long-term survival was investigated in a subgroup analysis of the SiLVER Study. Methods: Response to bridging, as defined by comparison of imaging at the time of listing and post-transplant pathology report, was categorized into controlled versus progressive disease (more than 20 per cent tumour growth or development of new lesions). Results: Of 525 patients with HCC who had liver transplantation, 350 recipients underwent pretransplant bridging therapy. Tumour progression despite bridging was an independent risk factor affecting overall survival (hazard ratio 1.80; P=0.005). For patients within the Milan criteria (MC) at listing, mean overall survival was longer for those with controlled versus progressive disease (6.8 versus 5.8 years; P<0.001). Importantly, patients with HCCs outside the MC that were downsized to within the MC before liver transplantation had poor outcomes compared with patients who never exceeded the MC (mean overall survival 6.2 versus 6.6 years respectively; P=0.030). Conclusion: Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best outcomes after liver transplantation. Downstaging into the limits of the MC did not improve the probability of survival. Prognostic factors determining the long-term success of liver transplantation in patients with hepatocellular carcinoma are still under discussion. A subgroup analysis of the SiLVER trial showed that disease control under bridging therapy is strongly associated with improved prognosis in terms of overall survival. However, in tumours exceeding the limits of the Milan criteria, downstaging did not restore the probability of survival compared with that of patients within the Milan criteria.

Published
2021

11. Erkrankungen der Leber

Author

Margreiter, R., Roeren, T., Schlumpf, R., Sieber, C., Wydler, J., Siewert, J. R., editor, Harder, F., editor, and Rothmund, M., editor

Published
2002
Full Text
View/download PDF

15. Der duale protektive Effekt von Tetrahydrobiopterin gegenüber frühen Parenchymschädigungen am murinen Pankreastransplantat

Author

Maglione, M., Oberhuber, R., Hengster, P., Hermann, M., Mark, W., Obrist, P., Werner-Felmayer, G., Werner, E. R., Margreiter, R., Brandacher, G., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

16. Ösophaguskarzinom

Author

Hölbling, N., Eckersberger, F., Friehs, G., Smolle-Jüttner, F.-M., Klepetko, W., Kogelnik, H. D., Lexer, G., Margreiter, R., Miller, K., Moritz, E., Niederle, B., Roka, R., Rosen, H., Schratter-Sehn, A., Schwamberger, K., Wenzl, E., and Smola, M. G., editor

Published
1999
Full Text
View/download PDF

23. AMS measurements of C-14, Cl-36, and Pu-239/240 samples taken in a 'small facility'

Author

Michel, M., Filby, A., Heinze, S., Margreiter, R., Strub, E., Michel, M., Filby, A., Heinze, S., Margreiter, R., and Strub, E.

Abstract

The release of nuclear facilities from regulatory control is commonly addressed by demonstrating that con-taminations are below 'clearance values'. AMS is commonly too laborious for a large number of samples, especially if nuclide vectors have been established, but it might be of interest for the release of a so-called 'small facility'. For this case study, a radiochemistry laboratory in Cologne, Germany was chosen. It was known that C-14, Cl-36 as well as 240Pu had been handled openly in this lab. There were no apparent contaminations, i.e., no alpha/beta contaminations that could be detected using a hand-held radiation monitor. Elevated values of C-14 were measured in three, increased values of Cl-36 in all and Pu-239 in only one of the examined samples. All measured activities are well below the release values, but it can be proven that the elements C-14, Cl-36, Pu-239 were handled openly in the 'small facility'.

Published
2022

26. Hepatocellular carcinoma progression during bridging before liver transplantation

Author

Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, and Publica

Subjects
Male, Carcinoma, Hepatocellular, Time Factor, Waiting Lists, AcademicSubjects/MED00910, Prognosi, Risk Factor, Middle Aged, Liver Transplantation, Treatment Outcome, Liver Neoplasm, Disease Progression, Female, Original Article, Survival Analysi, Neoplasm Recurrence, Local, AcademicSubjects/MED00010, Multivariate Analysi, Human
Abstract

Background Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria affecting the chance of long-term success. Here, the relationship between pretransplant bridging therapy and long-term survival was investigated in a subgroup analysis of the SiLVER Study. Methods Response to bridging, as defined by comparison of imaging at the time of listing and post-transplant pathology report, was categorized into controlled versus progressive disease (more than 20 per cent tumour growth or development of new lesions). Results Of 525 patients with HCC who had liver transplantation, 350 recipients underwent pretransplant bridging therapy. Tumour progression despite bridging was an independent risk factor affecting overall survival (hazard ratio 1.80; P = 0.005). For patients within the Milan criteria (MC) at listing, mean overall survival was longer for those with controlled versus progressive disease (6.8 versus 5.8 years; P

Published
2021

29. HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post-hoc analysis

Author

Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Werner J. M., Hornung M., Krah R., Gotz M., Schnitzbauer A. A., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Turrion V. S., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Werner J. M., Hornung M., Krah R., Gotz M., Schnitzbauer A. A., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Turrion V. S., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., and Neuhaus P.

Abstract

Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n = 88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n = 78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression + CNIs for >50% (B1; n = 44) or <50% (B2; n = 34) of the time. While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P = 0.0136) and group B2 (64.7%; P = 0.0326); Interestingly, further subgroup analysis revealed an increase (P = 0.0012) in liver enzyme values in group B2. Taken together, in HCV-infected patients with HCC and LTx, mTORi immunosuppression + CNIs yields excellent outcomes. Unexpectedly, higher levels of liver inflammation and poorer outcomes occur with mTORi monotherapy in the HCV+ subgroup.

Published
2020

37. Oesophaguskarzinom

Author

Weitensfelder, W., Eckersberger, F., Friehs, G., Funovics, J., Hölbling, N., Smolle-Jüttner, F.-M., Klepetko, W., Krisch, K., Lexer, G., Margreiter, R., Moritz, E., Niederle, B., Rainer, H., Roka, R., Rosen, H., Schwamberger, K., Seitz, W., Zängl, A., and Steindorfer, Peter, editor

Published
1990
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results